# Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

> **NCT05988372** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 50 (estimated)

## Conditions studied

- Locally Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine
- **DRUG:** Albumin-paclitaxel + Gemcitabine

## Key facts

- **NCT ID:** NCT05988372
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10-23
- **Primary completion:** 2023-10-23
- **Final completion:** 2026-10-23
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05988372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05988372, "Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT05988372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*